







Animal Health-IDRC: CBPP projects Funding

Najete SAFINI PhD Senior Program Officer, Animal Health July 24th, 2024 GF-TADs for Africa Second Meeting on CBPP, Lusaka, Zambia





A more sustainable and inclusive world

As part of Canada's foreign affairs and international development efforts, and with five regional offices and a global network of partners and researchers, we have the breadth and experience to respond to global challenges.


IDRC champions and funds research and innovation within and alongside developing regions to drive global change. We invest in high-quality research in developing countries, share knowledge with researchers and policymakers for greater uptake and use, and mobilize our global alliances to build a more sustainable and inclusive world.







- Mobilize alliances for impact: deepen and expand our collaboration and pursue new partnerships to grow the available resources for research.
- Move solutions forward thanks to alliance with the public, private, and other actors.
- Research that considers gender with other forms of inequality. This
 research ensures women, girls, and other marginalized groups are not
 left behind.
- IDRC helps build strong scientific institutions and systems to enable an environment that encourages high-quality research and innovation.
- We work with coalitions to amplify knowledge that transforms food systems so they become more sustainable and inclusive, support healthy diets, and improve community resilience




InnoVet-AMR

Innovative Veterinary Solutions for Antimicrobial Resistance Phase 1.0 2018-2023 Phase 2.0 2023-2027

> Phase 1.0 CAD 30 million

Phase 2.0 CAD 30 million

IDRC and DHSC-UK Reduce AMR



AQUADAPT

Nature-based Climate Solutions in Aquaculture in Asia-Pacific 2023-2027



Climate solutions in aquaculture IDRC and the Government of Canada



Livestock Vaccine Innovation Fund

2015 - 2024

- Accelerate the development of new vaccines against • neglected livestock diseases by supporting innovation and cutting-edge research
- Increase the efficacy, marketability and use of existing • livestock vaccines
- **Foster effective partnerships** between vaccine researchers • and public and private sector actors
- Focus on animal diseases posing the greatest risk to poor • **livestock keepers** in Sub-Saharan Africa, South and Southeast Asia BILL& MELINDA Canada


GATES foundation



Countries of Impact – LVIF



Partnerships




		Geographical spread of institutions within the evaluation sample												
		Upstream					Midstream				Downstream			
		109212/ 108514	108525/ 109475	108705	108706	108516/ 109271	108627/ 109261	109080	108632	108628	109275	109061	109062	109063
ation of titution	Я	JCVI J CRAIS VENTER INSTITUTE"	MONASH University AMESCOOK ARS	Voredun	WYSS SINSTITUTE HARVARD UNIVERSITY OF SASKATCHEMAN	CALGARY	Transformed Street Barrier	UNIVERSITY OF SASKATCHEWAN		d cirad	Tufts	Tufts	UF FLORIDA	
Locati Institu	LMIC	ILRI		ARC·LNR		Automatical and an and an	Last Contra de C		M.C.I. Santé Animale	(TIR)		AFROHUN		

Animal Health product pipeline



Stages of research and development of a product in the pharmaceutical industry



LVIF Approach

Private sector approach

Target product profiles Private sector evaluations Two-phased funding approach (go/no go funding)

Cohort approach & cross learning

Integrating gender in research knowledge translation & amplification Environmental assessment

Wraparound support

Intellectual property Assessing gaps in project sustainability

LVIF's Contribution



Synthetic vaccine for African Swine Fever

Discovery

Proof of Concept 🕨 E

Exploratory Development


Full Development

Regulatory Submission

Stewardship

Why is this necessary?

- ASF is the largest animal disease outbreak in the world.
- There is currently no vaccine or treatment against ASF.





Main Achievement

 Successfully used synthetic biological tools to modify and assemble a new synthetic ASF virus genome.

Benefits

- Demonstrated that CRISPR technology (gene editing) could produce virus mutants that are protective against ASF.
 - A potential new vaccine candidate is underway.

Women Rear

Discovery

Proof of Concept

Exploratory Development

Full Development

Regulatory Submission

Stewardship

Why is this necessary?

• Women smallholders are not having equitable access to vaccine.





Main Achievement

- Proof of concept reached for gender-inclusive vaccine delivery model. Model included audio messages through a mobile app, and drone delivery to health centres.
 - Collaboration between 3 partner critical for success (expert in gender transformative farmer trainings/ private service provider/ research partner)


Benefits

- Reduced vaccine wastage by 30%.
- Based on post-vaccination survey in March 2023, 82.5% of farmers reported having healthier livestock due to vaccinations.
- Current plans to expand to other districts in Ghana and other countries





DeLiVa project|Piloting a sustainable CCPP vaccine value chain in Borena Zone- Ethiopia through public-private Franchise model



Outcomes:

- ✓ The project has successfully designed and tested an alternative, private sector model of CCPP vaccine delivery that has improved availability, accessibility, and demand for CCPP vaccine.
- A project baseline assessment reported that the government operational budget for veterinary services for the four woredas in 2022 was 535,000 birr. In contrast, the income received by the four franchisees was 2,677,491 birr, approximately 5 times the government's annual operational budget for 2022
- ✓ this result shows an important part of the economic rationale for private sector involvement in vaccine delivery, and the willingness of pastoralists to pay for the service
- The project has also generated new knowledge about the factors that influence the uptake of CCPP vaccine by pastoralists, the role of women in CCPP vaccine delivery, and the potential for private sector delivery of CCPP vaccine

CBPP Subunit vaccine development

Discovery

Proof of Concept

Exploratory Development

Full Development

Regulatory Submission

Stewardship

Why is this necessary?

Clinical trials to develop a subunit vaccine for • contagious bovine pleuropneumonia in Kenya





Main Achievement

- 1. Key achievements include the development of a novel infection model for contagious bovine pleuropneumonia (CBPP) by VIDO scientists and Kenyan experts. This advancement significantly contributes to an Enhanced Disease Modeling.
- 2. The recombinant vaccine and ContavaxTM showed similar protective efficacy, approximately 52% and 51%, respectively.

Benefits

A potential new vaccine candidate is underway.

CBPP future funding TAHSSL: Transforming Animal-Health Solutions and Services for Low-and middle-income countries

\$CA 2 mil, to support TAHSSL in future project on CBPP

- Development and testing of a feasible and scalable CBPP control program in pastoral farming systems
- Partnership: ILRI, GALVMed, University of Cambridge, State Department of Veterinary Services, Kenya, Kenya Agricultural and Livestock Research Organization (KALRO).

03 WP out of 07 will be funded by IDRC.

Thank you for your attention